European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.

Marchetti M, Vannucchi AM, Mascarenhas JO, Alvarez-Larran A, Bose P, Gale RP, Harrison C, Hehlmann R, Kiladjian JJ, Koschmieder S, Mesa R, Passamonti F, Rambaldi A, Tefferi A, Barbui T.

Open source

DOI: 10.1038/s41408-025-01381-y
Published: 2025-11-24
Container: Blood Cancer J
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41408-025-01381-y,
  title = {European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.},
  author = {Marchetti M and  Vannucchi AM and  Mascarenhas JO and  Alvarez-Larran A and  Bose P and  Gale RP and  Harrison C and  Hehlmann R and  Kiladjian JJ and  Koschmieder S and  Mesa R and  Passamonti F and  Rambaldi A and  Tefferi A and  Barbui T.},
  year = {2025},
  journal = {Blood Cancer J},
  doi = {10.1038/s41408-025-01381-y},
  url = {https://doi.org/10.1038/s41408-025-01381-y}
}

RIS

TY  - JOUR
TI  - European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.
AU  - Marchetti M
AU  -  Vannucchi AM
AU  -  Mascarenhas JO
AU  -  Alvarez-Larran A
AU  -  Bose P
AU  -  Gale RP
AU  -  Harrison C
AU  -  Hehlmann R
AU  -  Kiladjian JJ
AU  -  Koschmieder S
AU  -  Mesa R
AU  -  Passamonti F
AU  -  Rambaldi A
AU  -  Tefferi A
AU  -  Barbui T.
PY  - 2025
JO  - Blood Cancer J
DO  - 10.1038/s41408-025-01381-y
UR  - https://doi.org/10.1038/s41408-025-01381-y
ER  -

APA

M, M., AM, V., JO, M., A, A., P, B., RP, G., C, H., R, H., JJ, K., S, K., R, M., F, P., A, R., A, T., & T., B. (2025). European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.. Blood Cancer J. https://doi.org/10.1038/s41408-025-01381-y

Source records

europe-pmc · retrieved 2026-09-27T02:23:05.603Z
doaj · retrieved 2026-09-27T02:23:05.604Z